Erratum: Differential peripheral blood gene expression profile based on her2 expression on primary (PLoS ONE (2014) 9:7 (e102764) DOI:10.1371/journal.pone.0102764);Differential peripheral blood gene expression profile based on Her2 expression on primary tumors of breast cancer patients

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Tudoran, Oana ^a   Virtic, Oana ^b   Balacescu, Loredana ^a   Pop, Laura ^b   Dragla, Flaviu ^a   Eniu, Alexandru ^a   Fetica, Bogdan ^a   Balacescu, Ovidiu ^a   Berindan Neagoe, Ioana ^a,b  

^a THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRANSCRIPTION FACTOR;

ADULT; AGED; ARTICLE; BASOPHIL; CANCER GROWTH; CCNA1 GENE; CDH1 GENE; CELL CYCLE REGULATION; CLINICAL ARTICLE; COHORT ANALYSIS; CTNNB1 GENE; DISEASE ASSOCIATION; DOWN REGULATION; EOSINOPHIL; ERBB2 GENE; FEMALE; GATA3 GENE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENETIC ANALYSIS; GENETIC CODE; GENETIC REGULATION; GENETIC TRANSCRIPTION; GLI1 GENE; HIC1 GENE; HUMAN; HUMAN CELL; IMMUNE SYSTEM; JUN GENE; KRT8 GENE; LEUKOCYTE; LYMPHOCYTE; MKI67 GENE; NEUTROPHIL; NOTCH1 GENE; ONCOGENE; PILOT STUDY; PRIMARY TUMOR; PROTEIN EXPRESSION; PTGS2 GENE; RASSF1 GENE; SFN GENE; SIGNAL TRANSDUCTION; SRC GENE; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION; BLOOD; BREAST TUMOR; GENETICS; HISTORY; MIDDLE AGED; PROTO ONCOGENE;

AGED; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENES, ERBB-2; HISTORY, 16TH CENTURY; HUMANS; MIDDLE AGED; TRANSCRIPTION, GENETIC;

EID: 84904890044     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110962     Document Type: Erratum

References (56)

1. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98: 10869-10874. (Pubitemid 32878711)
2. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
3. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, et al. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100: 8418-8423. (Pubitemid 36842560)
4. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, et al. (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295: 2492-2502. (Pubitemid 43854964)
5. Hu Z, Fan C, Oh DS, Marron JS, He X, et al. (2006) The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7: 96.
6. Sorlie T, Wang Y, Xiao C, Johnsen H, Naume B, et al. (2006) Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics 7: 127.
7. O'Brien KM, Cole SR, Tse CK, Perou CM, Carey LA, et al. (2010) Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res 16: 6100-6110.
8. Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, et al. (2010) Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 7: e1000279.
9. Dent S, Oyan B, Honig A, Mano M, Howell S (2013) HER2-targeted therapy in breast cancer: A systematic review of neoadjuvant trials. Cancer Treat Rev.
10. Chiorean R, Braicu C, Berindan-Neagoe I (2013) Another review on triple negative breast cancer. Are we on the right way towards the exit from the labyrinth? Breast 22: 1026-1033.
11. Twine NC, Stover JA, Marshall B, Dukart G, Hidalgo M, et al. (2003) Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma. Cancer Res 63: 6069-6075. (Pubitemid 37187512)
12. Han M, Liew CT, Zhang HW, Chao S, Zheng R, et al. (2008) Novel blood-based, five-gene biomarker set for the detection of colorectal cancer. Clin Cancer Res 14: 455-460. (Pubitemid 351226113)
13. Burczynski ME, Twine NC, Dukart G, Marshall B, Hidalgo M, et al. (2005) Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma. Clin Cancer Res 11: 1181-1189. (Pubitemid 40175769)
14. Aaroe J, Lindahl T, Dumeaux V, Saebo S, Tobin D, et al. (2010) Gene expression profiling of peripheral blood cells for early detection of breast cancer. Breast Cancer Res 12: R7.
15. Sharma P, Sahni NS, Tibshirani R, Skaane P, Urdal P, et al. (2005) Early detection of breast cancer based on gene-expression patterns in peripheral blood cells. Breast Cancer Res 7: R634-644.
16. Crabb SJ, Cheang MC, Leung S, Immonen T, Nielsen TO, et al. (2008) Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer. Clin Breast Cancer 8: 249-256. (Pubitemid 351962146)
17. Reyal F, Rouzier R, Depont-Hazelzet B, Bollet MA, Pierga JY, et al. (2011) The molecular subtype classification is a determinant of sentinel node positivity in early breast carcinoma. PLoS One 6: e20297.
18. Lucci A, Hall CS, Lodhi AK, Bhattacharyya A, Anderson AE, et al. (2012) Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol 13: 688-695.
19. Alix-Panabieres C, Vendrell JP, Slijper M, Pelle O, Barbotte E, et al. (2009) Fulllength cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer. Breast Cancer Res 11: R39.
20. Daskalaki A, Agelaki S, Perraki M, Apostolaki S, Xenidis N, et al. (2009) Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer. Br J Cancer 101: 589-597.
21. Lin XL, Wang XL, Ma B, Jia J, Yan Y, et al. (2012) HER2-specific T lymphocytes kill both trastuzumab-resistant and trastuzumab-sensitive breast cell lines in vitro. Chin J Cancer Res 24: 143-150.
22. Melani C, Sangaletti S, Barazzetta FM, Werb Z, Colombo MP (2007) Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res 67: 11438-11446. (Pubitemid 350248572)
23. Savino M, Parrella P, Copetti M, Barbano R, Murgo R, et al. (2009) Comparison between real-time quantitative PCR detection of HER2 mRNA copy number in peripheral blood and ELISA of serum HER2 protein for determining HER2 status in breast cancer patients. Cell Oncol 31: 203-211.
24. Savino M, Garrubba M, Parrella P, Baorda F, Copetti M, et al. (2007) Development of real-time quantitative reverse transcription-PCR for Her2 detection in peripheral blood from patients with breast cancer. Clin Chim Acta 384: 52-56. (Pubitemid 47247411)
25. Han M, Deng HY, Jiang R (2012) Effect of Trastuzumab on Notch-1 Signaling Pathway in Breast Cancer SK-BR3 Cells. Chin J Cancer Res 24: 213-219.
26. Pradeep CR, Kostler WJ, Lauriola M, Granit RZ, Zhang F, et al. (2012) Modeling ductal carcinoma in situ: a HER2-Notch3 collaboration enables luminal filling. Oncogene 31: 907-917.
27. Tan M, Li P, Klos KS, Lu J, Lan KH, et al. (2005) ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis. Cancer Res 65: 1858-1867. (Pubitemid 40478614)
28. Wang Z, Liu L, Wang M, Shen M, Li J, et al. (2012) NOTCH1 regulates migration and invasion of skin cancer cells by E-cadherin repression. Mol Cell Biochem 362: 35-41.
29. Dillon RL, Brown ST, Ling C, Shioda T, Muller WJ (2007) An EGR2/CITED1 transcription factor complex and the 14-3-3sigma tumor suppressor are involved in regulating ErbB2 expression in a transgenic-mouse model of human breast cancer. Mol Cell Biol 27: 8648-8657.
30. Wei G, Abraham BJ, Yagi R, Jothi R, Cui K, et al. (2011) Genome-wide analyses of transcription factor GATA3-mediated gene regulation in distinct T cell types. Immunity 35: 299-311.
31. Ji P, Agrawal S, Diederichs S, Baumer N, Becker A, et al. (2005) Cyclin A1, the alternative A-type cyclin, contributes to G1/S cell cycle progression in somatic cells. Oncogene 24: 2739-2744. (Pubitemid 40593102)
32. Chaturvedi P, Reddy MV, Reddy EP (1998) Src kinases and not JAKs activate STATs during IL-3 induced myeloid cell proliferation. Oncogene 16: 1749-1758. (Pubitemid 28175056)
33. Adler SH, Chiffoleau E, Xu L, Dalton NM, Burg JM, et al. (2003) Notch signaling augments T cell responsiveness by enhancing CD25 expression. J Immunol 171: 2896-2903. (Pubitemid 37093510)
34. Wahl SM, Vazquez N, Chen W (2004) Regulatory T cells and transcription factors: gatekeepers in allergic inflammation. Curr Opin Immunol 16: 768-774. (Pubitemid 39423667)
35. Su YW, Hao Z, Hirao A, Yamamoto K, Lin WJ, et al. (2011) 14-3-3sigma regulates B-cell homeostasis through stabilization of FOXO1. Proc Natl Acad Sci U S A 108: 1555-1560.
36. Ryan EP, Malboeuf CM, Bernard M, Rose RC, Phipps RP (2006) Cyclooxygenase-2 inhibition attenuates antibody responses against human papillomavirus-like particles. J Immunol 177: 7811-7819. (Pubitemid 44846297)
37. Andre F, Dieci MV, Dubsky P, Sotiriou C, Curigliano G, et al. (2013) Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer. Clin Cancer Res 19: 28-33.
38. Ignatiadis M, Singhal SK, Desmedt C, Haibe-Kains B, Criscitiello C, et al. (2012) Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J Clin Oncol 30: 1996-2004.
39. West NR, Milne K, Truong PT, Macpherson N, Nelson BH, et al. (2011) Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res 13: R126.
40. Denkert C, Darb-Esfahani S, Loibl S, Anagnostopoulos I, Johrens K (2011) Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy. Semin Immunopathol 33: 341-351.
41. Muller-Tidow C, Diederichs S, Schrader MG, Vogt U, Miller K, et al. (2003) Cyclin A1 is highly expressed in aggressive testicular germ cell tumors. Cancer Lett 190: 89-95. (Pubitemid 36106559)
42. Liao C, Li SQ, Wang X, Muhlrad S, Bjartell A, et al. (2004) Elevated levels and distinct patterns of expression of A-type cyclins and their associated cyclindependent kinases in male germ cell tumors. Int J Cancer 108: 654-664. (Pubitemid 38076396)
43. Rivera A, Mavila A, Bayless KJ, Davis GE, Maxwell SA (2006) Cyclin A1 is a p53-induced gene that mediates apoptosis, G2/M arrest, and mitotic catastrophe in renal, ovarian, and lung carcinoma cells. Cell Mol Life Sci 63: 1425-1439. (Pubitemid 43939022)
44. Coletta RD, Christensen K, Reichenberger KJ, Lamb J, Micomonaco D, et al. (2004) The Six1 homeoprotein stimulates tumorigenesis by reactivation of cyclin A1. Proc Natl Acad Sci U S A 101: 6478-6483. (Pubitemid 38585999)
45. Kitkumthorn N, Yanatatsanajit P, Kiatpongsan S, Phokaew C, Triratanachat S, et al. (2006) Cyclin A1 promoter hypermethylation in human papillomavirusassociated cervical cancer. BMC Cancer 6: 55.
46. Nakamaki T, Hamano Y, Hisatake J, Yokoyama A, Kawakami K, et al. (2003) Elevated levels of cyclin A1 and A (A2) mRNA in acute myeloid leukaemia are associated with increased survival. Br J Haematol 123: 72-80. (Pubitemid 37222760)
47. Ignatiadis M, Perraki M, Apostolaki S, Politaki E, Xenidis N, et al. (2007) Molecular detection and prognostic value of circulating cytokeratin-19 messenger RNA-positive and HER2 messenger RNA-positive cells in the peripheral blood of women with early-stage breast cancer. Clin Breast Cancer 7: 883-889.
48. Korantzis I, Kalogeras KT, Papaxoinis G, Kotoula V, Koutras A, et al. (2012) Expression of angiogenic markers in the peripheral blood of patients with advanced breast cancer treated with weekly docetaxel. Anticancer Res 32: 4569-4580.
49. Muller HM, Widschwendter A, Fiegl H, Ivarsson L, Goebel G, et al. (2003) DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res 63: 7641-7645. (Pubitemid 37466689)
50. Kioulafa M, Kaklamanis L, Mavroudis D, Georgoulias V, Lianidou ES (2009) Prognostic significance of RASSF1A promoter methylation in operable breast cancer. Clin Biochem 42: 970-975.
51. Gobel G, Auer D, Gaugg I, Schneitter A, Lesche R, et al. (2011) Prognostic significance of methylated RASSF1A and PITX2 genes in blood- and bone marrow plasma of breast cancer patients. Breast Cancer Res Treat 130: 109-117.
52. Buhmeida A, Merdad A, Al-Maghrabi J, Al-Thobaiti F, Ata M, et al. (2011) RASSF1A methylation is predictive of poor prognosis in female breast cancer in a background of overall low methylation frequency. Anticancer Res 31: 2975-2981.
53. Xu J, Shetty PB, Feng W, Chenault C, Bast RC Jr, et al. (2012) Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome. BMC Cancer 12: 243.
54. Feng W, Shen L, Wen S, Rosen DG, Jelinek J, et al. (2007) Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res 9: R57.
55. Chang HW, Chan A, Kwong DL, Wei WI, Sham JS, et al. (2003) Evaluation of hypermethylated tumor suppressor genes as tumor markers in mouth and throat rinsing fluid, nasopharyngeal swab and peripheral blood of nasopharygeal carcinoma patient. Int J Cancer 105: 851-855. (Pubitemid 36706111)
56. Cho YH, Yazici H, Wu HC, Terry MB, Gonzalez K, et al. (2010) Aberrant promoter hypermethylation and genomic hypomethylation in tumor, adjacent normal tissues and blood from breast cancer patients. Anticancer Res 30: 2489-2496.